/
Personalizing COPD Therapy According to Recent Personalizing COPD Therapy According to Recent

Personalizing COPD Therapy According to Recent - PowerPoint Presentation

friendma
friendma . @friendma
Follow
343 views
Uploaded On 2020-06-16

Personalizing COPD Therapy According to Recent - PPT Presentation

Clinical Trial Evidence Introduction Therapeutic Recommendations Therapeutic Recommendations in Groups B and D Bronchodilators in Stable COPD ICS in Stable COPD COPD Potential AEs of ICS Treatment ID: 778491

exacerbations copd laba ics copd exacerbations ics laba study lama design ind lung gly recommendations sfc flame aes exacerbation

Share:

Link:

Embed:

Download Presentation from below link

Download The PPT/PDF document "Personalizing COPD Therapy According to ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Personalizing COPD Therapy According to Recent Clinical Trial Evidence

Slide2

Slide3

Introduction

Slide4

Therapeutic Recommendations

Slide5

Therapeutic Recommendations in Groups B and D

Slide6

Bronchodilators in Stable COPD

Slide7

ICS in Stable COPD

Slide8

COPD Potential AEs of ICS Treatment

Slide9

Slide10

Diabetes Onset on ICS

Slide11

FLAME: IND/GLY vs SFC for COPD Exacerbations in High-Risk Population

Slide12

FLAME: Primary Endpoint Noninferiority and Superiority for IND/GLY vs SFC

Slide13

FLAME: Effect of IND/GLY on Time to First Exacerbation Compared With SFC

Slide14

Triple StudiesComparisons

Slide15

Triple StudiesComparisons (cont)

Slide16

TRIBUTELABA/LAMA/ICS vs LABA/LAMA

Slide17

TRIBUTERate of Moderate and Severe Exacerbations

Slide18

TRIBUTE Main AEs and Serious AEs

Slide19

IMPACT

LABA/LAMA/ICS vs LABA/ICS + LABA/LAMA

Slide20

Evolution of Exacerbations

Slide21

IMPACTEffect on Pneumonia

Slide22

SUNSET Trial Design

Slide23

Primary Endpoint: Change From Baseline in Postdose Trough FEV1 (Noninferiority Analysis)

Slide24

SUNSET Rate of COPD Exacerbations During the 26-Week Treatment Period

Slide25

Exacerbation Rate Analysis and Blood Eosinophil Levels

Slide26

WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD

Slide27

WISDOM Post-Hoc AnalysisICS Withdrawal and Exacerbation Risk

Slide28

DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations

Slide29

DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations (cont)

Slide30

GOLD Recommendations in the Group D

Slide31

Airway Obstruction and Lung Hyperinflation in COPD Are Linked to an Impaired Left Ventricular Diastolic Filling

Slide32

Interaction of Heart and Lung in COPD Hyperinflation vs Diastolic Filling

Slide33

CLAIM Study Design

Slide34

CLAIM Study Results

Slide35

Lung Deflation With Indacaterol/Glycopyrronium Improves Pulmonary Microvascular Blood Flow

Slide36

Concluding Remarks

Slide37